NEW YORK – Tempus on Monday announced a strategic collaboration with Janssen Research & Development in oncology clinical development programs and data science.
For this collaboration, Tempus said that it is developing a predictive machine-learning model to improve enrollment in biomarker-driven clinical trials for Janssen R&D, a unit of Johnson & Johnson's Janssen Pharmaceutica. According to Chicago-based Tempus, Janssen is looking for a method to speed up the identification of patients with specific tumor features that match the requirements of trials.